Q2 2025 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2025-08-12 · accession 0001104659-25-076815
$123.8M
Reported value
6
Positions
2025-06-30
Period end
The Brief · Foresite Capital Management IV, LLC · Q2 2025
AI · grounded in 13F
Foresite Capital Management IV, LLC established a new position in Pharvaris N.V. valued at $77.6M. The fund also initiated a stake in Maze Therapeutics Inc MAZE for $25.9M. Additional new positions include Lyell Immunopharma, Inc. LYEL at $7.1M and Xenon Pharmaceuticals Inc XENE at $5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $77.6M | 62.7% | 4,410,581 | Common | SOLE |
| 578784100 | MAZE | Maze Therapeutics Inc | $25.9M | 20.9% | 2,111,919 | Common | SOLE |
| 55083R203 | LYEL | Lyell Immunopharma, Inc. | $7.1M | 5.72% | 800,399 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $5.0M | 4.05% | 160,000 | Common | SOLE |
| 50127T109 | KURA | Kura Oncology, Inc. | $4.7M | 3.81% | 816,882 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $3.5M | 2.79% | 1,000,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.